Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD36 antibody
- Development stage
- Unknown
- Lead developer
- Pilatus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-CD36 antibodies are a class of monoclonal antibodies designed to target Platelet glycoprotein 4 (CD36), a scavenger receptor that plays a key role in lipid uptake and fatty acid metabolism. In the tumor microenvironment, CD36 is selectively upregulated on regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and exhausted CD8+ T cells, facilitating metabolic adaptation that drives immunosuppression. By blocking CD36-mediated lipid uptake, therapeutic antibodies such as PLT012 (developed by Pilatus Biosciences) disrupt this metabolic checkpoint, depleting immunosuppressive cell populations and restoring the effector function of cytotoxic T cells and NK cells. This approach is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including hepatocellular carcinoma.
- Other names
- anti-CD36 monoclonal antibodyanti-CD-36 monoclonal antibodyanti-CD 36 monoclonal antibodyhumanized anti-CD36 antibody
02
Targets
CD36 (CD36 antigen)
Beyond the preview
Go deeper on anti-CD36 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD36 antibody.